On Tuesday shares of Zafgen, Inc. (NASDAQ:ZFGN) closed at $45.57.On Mar 12, Zafgen, Inc. (NASDAQ:ZFGN) announced that it will host a conference call on Thursday, March 19, 2015 at 4:30 p.m. ET to discuss its financial results for the fourth quarter and the full year ended December 31, 2014.
Alpha Natural Resources, Inc. (NYSE:ANR) in last trading activity decreased -5.90% to close at $0.81. Company weekly performance is -20.66% while its quarterly performance stands at -46.76%. Alpha Natural Resources, Inc. (NYSE:ANR) is -84.07% away from its 52 week high. A miner at Alpha Natural Resources (NYSE:ANR) affiliate Paramont Coal Company has suffered a fatal injury at Deep Mine 41 near McClure, Virginia.
On Tuesday shares of Esperion Therapeutics, Inc. (NASDAQ:ESPR) closed at $99.60. Company’s EPS growth for next 5 years is recorded as -3.10%. Esperion Therapeutics Inc. (NASDAQ:ESPR) announced positive top-line results from ETC-1002-009, a Phase 2b study evaluating the efficacy and safety of ETC-1002 (bempedoic acid) compared with placebo in patients with hypercholesterolemia on stable statin therapy.
Burlington Stores, Inc. (NYSE:BURL) in last trading activity advanced 2.11% to close at $58.59. Company weekly performance is 2.47% while its quarterly performance stands at 28.83%. Burlington Stores, Inc. (NYSE:BURL) is -1.00% away from its 52 week high. Burlington Stores, Inc. (NYSE:BURL), announced its results for the fourth quarter and fiscal year ended January 31, 2015. Net sales increased 11.3%, or $151.1 million, to $1,485.4 million. This increase includes the 6.7% increase in comparable store sales, as well as an increase of $66.9 million from new and non-comparable stores.
On last trading day Myriad Genetics Inc. (NASDAQ:MYGN) decreased -0.16% to close at $36.38. Its volatility for the week is 2.68% while volatility for the month is 3.24%. MYGN’s sales growth for past 5 years was 19.00% and its EPS growth for past 5 years was 10.30%. Myriad Genetics Inc. (NASDAQ:MYGN) monthly performance is 6.91%. Myriad Genetics, Inc. (NASDAQ:MYGN) announced an expansion of the Company’s collaboration with BioMarin Pharmaceutical Inc. Under the expanded collaboration, BioMarin will use Myriad’s myChoice HRD™ companion diagnostic test to prospectively identify patients with metastatic breast, ovarian and potentially other tumor types that may be sensitive to talazoparib. Financial terms were not disclosed.